Status
Conditions
Treatments
About
To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO [for use outside the United States [OUS] only]) in subjects with unprotected left main coronary artery disease by comparing to coronary artery bypass graft surgery.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
* Inclusion criteria for RCT:
Unprotected left main coronary artery (ULMCA) disease with angiographic diameter stenosis (DS) ≥70% requiring revascularization, or
ULMCA disease with agniographic DS >=50% but < 70% requiring revascularization, with one or more of the following present:
Left Main Equivalent Disease
Clinical and anatomic eligibility for both PCI and CABG
Silent ischemia, stable angina, unstable angina or recent MI
Ability to sign informed consent and comply with all study procedures including follow-up for at least three years
Exclusion criteria
* Clinical exclusion criteria:
Angiographic exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
1,905 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal